Updates

July 18, 2026 The Manager - Listing National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 The Manager – Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai - 400001 Dear Sir/ Madam Sub: Business Responsibility and Sustainability Report for the financial year ended March 31, 2026 Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility and Sustainability Report for financial year 2025-26 along with the Independent Practioners’ Limited Assurance Report provided by KPMG Assurance and Consulting Services LLP, which also forms part of the Annual Report for financial year 2025-26. This is for your kind information and records. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No. 25784 Encl: as above AstraZeneca Pharma India Limited Business Responsibility & Sustainability Report Director’s Message The interconnection between planetary and population health has never been more evident. Climate change, nature Our commitment to operating a responsible, resilient loss, chronic disease burden, ageing populations and and sustainable business is reflected in how we manage strained health systems are converging to threaten progress sustainability-related impacts, risks, and opportunities. and widen health inequities, with the greatest impacts felt by At AstraZeneca, we’re committed to improving the health the most vulnerable. of people, society and the planet. Recognising the strong As a science-led, patient-focused company, we recognise connection between business growth and resilience, and that addressing these interconnected challenges requires the need to address the major health challenges of our time, focused action where we can drive meaningful change. our approach to Sustainability focuses on how we make a sustainable impact and how we do business. About This Report How we make a sustainable impact: We are a global, science-led, patient-focused Through the power of science and innovation, we are taking pharmaceutical business. We are committed to excellence action on climate and nature, health equity and health in the research, development and commercialisation of systems resilience. We collaborate with governments, health prescription medicines. We aim to transform the lives of systems, patient groups, academia and NGO’s to focus our patients with improved outcomes and a better quality of life. shared efforts where we can have the greatest impact — on local, regional and global health. Our approach to sustainability Recognising the interconnection between business growth How we do business: and addressing the major health challenges of our time, our We are guided by our Values and invest in our people to Sustainability strategy focuses on how we do business and create long-term value, resilience and trust by operating how we make a positive impact — for the health of people, responsibly, ethically and with robust governance. society and the planet. 92 | Annual Report 2025-26 Corporate Overview Statutory Reports Financial Statements Section A – General Disclosures I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Listed Entity L24231KA1979PLC003563 2. Name of the listed entity AstraZeneca Pharma India Limited 3. Year of incorporation 1979 4. Registered office address Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore- 560045, Karnataka, India 5. Corporate address Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore- 560045, Karnataka, India 6. E-mail comp.secy@astrazeneca.com 7. Telephone +91 80 6774 8000 8. Website www.astrazeneca.com/india 9. Financial year for which reporting is being done 2025-26 10. Name of the Stock Exchange(s) where shares are BSE Limited and National Stock Exchange of India Limited listed 11. Paid-up capital INR 50,000,000 12. Name and contact details (telephone, email address) Ms. Tanya Sanish of the person who may be contacted in case of any Contact no: 080 - 67748000 queries on the BRSR report E-mail Id: comp.secy@astrazeneca.com 13. Reporting boundary Disclosure under this BRSR is on standalone basis. 14. Name of assurance provider KPMG Assurance and Consulting Services LLP 15. Type of assurance obtained Limited Assurance on BRSR Core Indicators only II. PRODUCTS AND SERVICES 16. Details of business activities (accounting for 90% of the turnover on a standalone basis) Description of Main Activity Description of Business Activity Percentage of Turnover of the entity Pharmaceuticals Marketing and trading of pharmaceutical products 90 17. Products/Services sold by the entity (accounting for 90% of the entity’s turnover on a consolidated basis) Product/Service NIC Code Percentage of total Turnover contributed Drugs and Pharmaceutical products 477 100 III. OPERATIONS 18. Number of locations where plants and/or operations/offices of the entity are situatede Number of plant (including Location Number of offices Total manufacturing plant & warehouse) National 1* 4 5 International 0 0 0 *During the year under review, manufacturing activities at this site were ceased. AstraZeneca Pharma India Limited 19. Markets served by the entity: a. Number of locations Locations Number National (Number of States) Pan-India International (No. of Countries) 1 (Nepal) b. What is the contribution of exports as a percentage of the total turnover of the entity? Out of total turnover of ` 22,755.8 million, the export sales contributed ` 1,175.6 million (5.2%) during the financial year 2025-26. c. A brief on types of customers Our Company’s customer base includes distributors, hospitals, and Government institutions. IV. EMPLOYEES 20. Details as at the end of Financial Year a. Employees and workers (including differently abled): Male Female Particulars Total No. of Male Percentage No. of Female Percentage Employees (%) of the total Employees of total Employees 1 Permanent 760 558 73 202 27 2 Other than Permanent 0 0 0 0 0 Total employees 760 558 73 202 27 Workers 1 Permanent 0 0 0 0 0 2 Other than Permanent 0 0 0 0 0 Total 0 0 0 0 0 b. Differently abled Employees and workers: Male Female Particulars Total No. of Male Percentage No. of Female Percentage Employees (%) of the total Employees of total Differently Abled Employees 1 Permanent 1 1 100 0 0 2 Other than Permanent 0 0 0 0 0 Total differently abled employees 1 1 100 0 0 Workers 1 Permanent 0 0 0 0 0 2 Other than Permanent 0 0 0 0 0 Total differently abled workers 0 0 0 0 0 94 | Annual Report 2025-26 Corporate Overview Statutory Reports Financial Statements 21. Participation/Inclusion/Representation of women No. and percentage of Females Particulars Total No. of women Percentage (%) representation of total Board of Directors 6 5 83.33 Key Management Personnel 3 2 66.7 22. Turnover rate for permanent employees and workers (trend for past 3 years) Turnover rate in FY 2025-26 (%) Turnover rate in FY 2024-25 (%) Turnover rate in FY 2023-24 (%) Particulars Male Female Total Male Female Total Male Female Total Permanent Employees 17.35 14.85 16.72 25.26 20.74 24.19 11 14 12 Permanent Workers *NA *NA *NA 13.79 37.50 16.67 2 45 6 *NA –Turnover in Permanent Workers is due to redundancies on account of Factory closure in FY 2025-26 i.e. all permanent workers left during the year on account of factory closure. V. HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES) 23. Names of holding / subsidiary / associate companies / joint ventures Name of the holding / subsidiary Indicate whether Percentage (%) Does the entity indicated in column A / associate companies / joint holding/ Subsidiary/ of shares held by participate in the Business Responsibility ventures (column A) Associate/ Joint Venture listed entity initiatives of the li [Showing first 8,000 characters — download PDF for full document]